ArticleFrontiers in microbiology2016
ESBL-Producing
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 122 citations in OpenAlex.
- Phenotypic and genotypic characterization of biofilm-forming Escherichia coli from subclinical bovine mastitis and association with antimicrobial resistance.BMC veterinary research · 2026Article
- Antimicrobial Susceptibility and Characterization of Extended-Spectrum β-Lactamases inMicroorganisms · 2026Article
- Molecular epidemiology of ESBL-producing Escherichia coli causing clinical and subclinical bovine mastitis: associations between multidrug resistance, virulence genes, and phylogroups.Veterinary research communications · 2026Article
- Detection of Selected Extended-Spectrum β-Lactamase (ESBL) Genes inVeterinary medicine international · 2026Article
- Characterization ofFrontiers in veterinary science · 2026Article
- Cefoxitin inhibits the formation of biofilm involved in antimicrobial resistance MDRAnimal biotechnology · 2025Article
- The evaluation of antimicrobial resistance rates in infections caused by uropathogenicIranian journal of microbiology · 2025Article
- Article
- Threats across boundaries: the spread of ESBL-positiveFrontiers in microbiology · 2025Review
- Zoonotic potential of ESBL-producing coliforms in pastorally managed ruminants with subclinical mastitis in Plateau State, Nigeria.Frontiers in antibiotics · 2025Article
- Epidemiology and Molecular Characterisation of Multidrug-ResistantVeterinary sciences · 2024Article
- Prevalence and molecular characterization of multi-resistantAnimal biotechnology · 2024Article
- Extended-Spectrum Beta-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2024Review
- Multiple-Drug Resistant Shiga Toxin-ProducingTropical medicine and infectious disease · 2024Article
- Article
- Current epidemiologic features and health dynamics of ESBL-producingBiosafety and health · 2024Review
- Prevalence and molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolates from dairy cattle with endometritis in Gansu Province, China.BMC veterinary research · 2024Article
- Detection of extended-spectrum β-lactamase-producingVeterinary world · 2023Review
- Comparative Genomic Analyses of Lactococcus garvieae Isolated from Bovine Mastitis in China.Microbiology spectrum · 2023Article
- Molecular characterization and antibiotic resistance profile of ESBL-producingVeterinary world · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of pathogenic multi-drug resistant (MDR) extended-spectrum β-lactamase (ESBL)-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.